the shift in adhd prescription drug claims and the impact of covid-19
by the end of 2023, more women in canada were being prescribed adhd medications than any other demographic. historically, males under the age of 18 were the most likely to get prescriptions for adhd medication. still, the data from reformulary shows the change happening right around the time the covid-19 pandemic began.
in 2020, males accounted for 57.8 per cent of adhd drug claims, while females made up 39 per cent, respectively. then, in 2023, the shift occurred, with females making more claims for adhd medication at a rate of 49.4 per cent compared to males at a rate of 47.3 per cent. an additional 3.3 per cent of claimants did not identify their sex as male or female.
when broken down into age groups, the data from reformulary shows that female adhd claimants between 25 and 44 rose by 205.2 per cent in 2023, compared to males in the same age group, which still saw a significant increase of 98.2 per cent.
“i think it’s a fact of going into this switch of my daily routine of going to work, and then all of a sudden, we’re at home with others working, maybe remote, or others not working because maybe your work can’t be done remotely,” she said. “it gives you more time to sit down and think—that space to analyze things that may have been there in the air forever but just being occupied the rest of the day and not thinking about it.”
other medical professionals have come to similar conclusions. in an article published by self, dr. ellen littman, a clinical psychologist, and co-author of the book understanding girls with adhd, commented that women who have yet to receive a clinical diagnosis for adhd have a higher likelihood of experiencing comorbid mood changes, including increased anxiety and depression, in response to emergency events such as the pandemic.